Literature DB >> 15813855

The immune response to primary EBV infection: a role for natural killer cells.

Hilary Williams1, Karen McAulay, Karen F Macsween, Neil J Gallacher, Craig D Higgins, Nadine Harrison, Anthony J Swerdlow, Dorothy H Crawford.   

Abstract

The role of antigen-specific CD3(+)CD8(+) cytotoxic T cells in the control of primary Epstein-Barr Virus (EBV) infection is well established. However, time is required for the antigen-specific immune response to develop and expand. In contrast, innate immune responses, such as natural killer (NK) cells, are considered vital early in the infection process. We analysed the scale, phenotype and function of the NK cell response during symptomatic primary EBV infection, infectious mononucleosis (IM) and showed that NK cell numbers were significantly elevated both at diagnosis of IM and in the first month following diagnosis. There were also significant changes in cell phenotype and function, an increase in the proportion of CD56(bright) cells at diagnosis, and freshly isolated cells showing an enhanced ability to kill EBV-infected cell lines. Moreover, in our cohort of IM patients higher NK cell counts were associated with significantly lower viral load in peripheral blood. Our results suggest NK cells have an important role in the control of primary EBV infection by eliminating infected B cells and augmenting the antigen-specific T cell response via release of immunomodulatory cytokines. The magnitude of the NK cell response may ultimately determine whether primary EBV infection has a clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15813855     DOI: 10.1111/j.1365-2141.2005.05452.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  59 in total

Review 1.  Infectious Mononucleosis.

Authors:  Samantha K Dunmire; Kristin A Hogquist; Henry H Balfour
Journal:  Curr Top Microbiol Immunol       Date:  2015       Impact factor: 4.291

2.  Association of GATA2 Deficiency With Severe Primary Epstein-Barr Virus (EBV) Infection and EBV-associated Cancers.

Authors:  Jeffrey I Cohen; Lesia Dropulic; Amy P Hsu; Christa S Zerbe; Tammy Krogmann; Kennichi Dowdell; Ronald L Hornung; Jana Lovell; Nancy Hardy; Dennis Hickstein; Edward W Cowen; Katherine R Calvo; Stefania Pittaluga; Steven M Holland
Journal:  Clin Infect Dis       Date:  2016-05-11       Impact factor: 9.079

Review 3.  The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease.

Authors:  Olivia L Hatton; Aleishia Harris-Arnold; Steven Schaffert; Sheri M Krams; Olivia M Martinez
Journal:  Immunol Res       Date:  2014-05       Impact factor: 2.829

Review 4.  Progress and problems in understanding and managing primary Epstein-Barr virus infections.

Authors:  Oludare A Odumade; Kristin A Hogquist; Henry H Balfour
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 5.  Natural killer cell responses during viral infections: flexibility and conditioning of innate immunity by experience.

Authors:  Silvia M Vidal; Salim I Khakoo; Christine A Biron
Journal:  Curr Opin Virol       Date:  2011-12       Impact factor: 7.090

6.  Cognate HLA absence in trans diminishes human NK cell education.

Authors:  Vanessa Landtwing; Ana Raykova; Gaetana Pezzino; Vivien Béziat; Emanuela Marcenaro; Claudine Graf; Alessandro Moretta; Riccarda Capaul; Andrea Zbinden; Guido Ferlazzo; Karl-Johan Malmberg; Obinna Chijioke; Christian Münz
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

7.  EBV-related lymphoproliferative disease complicating therapy with the anti-CD2 monoclonal antibody, siplizumab, in patients with T-cell malignancies.

Authors:  Deirdre O'Mahony; John C Morris; Maryalice Stetler-Stevenson; Helen Matthews; Margaret R Brown; Thomas Fleisher; Stefania Pittaluga; Mark Raffeld; Paul S Albert; Dirk Reitsma; Karen Kaucic; Luz Hammershaimb; Thomas A Waldmann; John E Janik
Journal:  Clin Cancer Res       Date:  2009-03-17       Impact factor: 12.531

8.  Epstein-Barr virus negativity among individuals older than 60 years is associated with HLA-C and HLA-Bw4 variants and tonsillectomy.

Authors:  Bojana Durovic; Olivier Gasser; Patrick Gubser; Jörg Sigle; Hans H Hirsch; Martin Stern; Andreas Buser; Christoph Hess
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

9.  Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein-Barr virus infection.

Authors:  Obinna Chijioke; Anne Müller; Regina Feederle; Mario Henrique M Barros; Carsten Krieg; Vanessa Emmel; Emanuela Marcenaro; Carol S Leung; Olga Antsiferova; Vanessa Landtwing; Walter Bossart; Alessandro Moretta; Rocio Hassan; Onur Boyman; Gerald Niedobitek; Henri-Jacques Delecluse; Riccarda Capaul; Christian Münz
Journal:  Cell Rep       Date:  2013-12-19       Impact factor: 9.423

10.  Cutting edge: NKG2C(hi)CD57+ NK cells respond specifically to acute infection with cytomegalovirus and not Epstein-Barr virus.

Authors:  Deborah W Hendricks; Henry H Balfour; Samantha K Dunmire; David O Schmeling; Kristin A Hogquist; Lewis L Lanier
Journal:  J Immunol       Date:  2014-04-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.